MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Repligen Corporation Income Statement 2011-2026 | RGEN
Annual Income Statement Repligen Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
10.8 M | 9.54 M | 14.6 M | 10.1 M | 4.91 B | 2.44 B | 1.37 B | 970 M | 728 M | 789 M | 501 M | 213 M | 123 M |
Shares |
55.7 K | 55.5 K | 55 K | 52.6 K | 48.3 M | 43.8 M | 38.2 M | 33.6 M | 32.9 M | 32.5 M | 31.7 M | 30.9 M | 30.8 M |
Historical Prices |
193 | 172 | 265 | 192 | 92.5 | 52.7 | 36.3 | 30.8 | 28.3 | 19.8 | 13.6 | 6.28 | 3.47 |
Net Income |
35.6 M | 186 M | 128 M | 59.9 M | 21.4 M | 16.6 M | 28.4 M | 11.7 M | 9.34 M | 8.17 M | 16.1 M | 14.2 M | -43.5 K |
Revenue |
632 M | 802 M | 671 M | 366 M | 270 M | 194 M | 141 M | 105 M | 83.5 M | 63.5 M | 68.2 M | 62.3 M | 27.3 M |
Cost of Revenue |
354 M | 346 M | 279 M | 157 M | 119 M | 86.5 M | 67 M | 47.1 M | - | - | - | - | - |
Gross Profit |
- | - | - | - | 151 M | 108 M | 74.2 M | 57.4 M | 48.3 M | 35.5 M | 43 M | 35.1 M | 20.2 M |
Operating Income |
47.7 M | 225 M | 167 M | 69.8 M | 36.1 M | 26 M | 14 M | 16 M | 13.8 M | 10.7 M | 22.9 M | 11.1 M | -374 K |
Interest Expense |
8.12 M | -9.53 M | -1.17 M | 10.8 M | 9.29 M | 6.71 M | 6.44 M | 3.77 M | 32 K | 50 K | 50 K | 56.7 K | 26.2 K |
EBITDA |
116 M | 276 M | 206 M | 96.9 M | 57 M | 41.8 M | 24.5 M | 24.6 M | 22.4 M | 16.8 M | 26.1 M | 14.9 M | 1.3 M |
Operating Expenses |
- | - | - | - | 115 M | 81.5 M | 60.2 M | 38.2 M | 30.4 M | 22.8 M | 20 M | 23.7 M | 20.5 M |
General and Administrative Expenses |
219 M | 216 M | 184 M | 120 M | 95.6 M | 65.7 M | 51.5 M | 30.9 M | 24.7 M | 17.2 M | 12.7 M | 13.2 M | 8.02 M |
All numbers in USD currency
Quarterly Income Statement Repligen Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
56.3 K | 56.2 K | 56.1 K | 56.1 M | 56 K | 55.9 K | 55.8 K | 55.8 M | 55.8 K | 55.7 K | 55.6 K | 55.6 M | 55.5 K | 55.4 K | 55.4 K | 55.3 M | 55 K | 54.9 M | 54.8 K | 54.8 M | 52.5 M | 52.4 M | 52.1 M | 52.1 M | 50.9 M | 46.4 M | 44 M | 43.9 M | 43.8 K | 43.7 K | 43.6 K | 43.6 M | 41.2 M | 34.1 M | 33.9 M | 33.8 M | 33.8 M | 33.6 M | 33 M | 32.9 M | 32.9 M | 32.9 M | 32.8 M | 32.7 M | 32.7 M | 32.2 M | 32 M | 31.9 M | 31.9 M | 31.6 M | 31.2 M | 31.1 M | 30.9 M | 30.8 M | 30.7 M | 30.7 M | 30.8 M | 30.8 M | 30.8 M |
Net Income |
14.9 M | 14.9 M | 5.83 M | - | -654 K | 5.71 M | 3.3 M | - | 16.9 M | 20.1 M | 28.8 M | - | 40.4 M | 49.9 M | 47 M | - | 33.5 M | 36.2 M | 29.4 M | 19.7 M | 14.6 M | 15.9 M | 9.82 M | 3.6 M | 1.66 M | 8.1 M | 8.05 M | 5.64 M | 4.79 M | 2.74 M | 3.45 M | 12.2 M | 4.67 M | 8.44 M | 3.07 M | 5.03 M | 1.16 M | 3.87 M | 1.62 M | 265 K | 2.54 M | 3.61 M | 2.93 M | -398 K | 1.47 M | 2.82 M | 4.28 M | 3.33 M | 5.89 M | 4.54 M | 2.34 M | 9.55 M | 1.81 M | 1.57 M | 1.23 M | -2.16 M | 605 K | -55 K | -2.03 M |
Revenue |
189 M | 182 M | 169 M | - | 155 M | 159 M | 153 M | - | 141 M | 159 M | 183 M | - | 201 M | 208 M | 206 M | - | 178 M | 163 M | 143 M | 109 M | 94.1 M | 87.5 M | 76.1 M | 69.5 M | 69.4 M | 70.7 M | 60.6 M | 51.9 M | 49.5 M | 47.7 M | 44.8 M | 41.6 M | 36.6 M | 32.5 M | 30.6 M | 25.6 M | 24.7 M | 29.2 M | 25.1 M | 21.4 M | 19.8 M | 21.5 M | 20.8 M | 16.4 M | 15.3 M | 15.6 M | 16.3 M | 15.4 M | 18.8 M | 17.5 M | 16.5 M | 18.8 M | 15.1 M | 15.5 M | 12.8 M | 7.16 M | 8.63 M | 7.65 M | 5.91 M |
Cost of Revenue |
88.3 M | 91.2 M | 78.4 M | - | 77.4 M | 77.3 M | 76.4 M | - | 105 M | 79.3 M | 81.8 M | - | 86.5 M | 86.3 M | 82.4 M | - | 75.5 M | 62 M | 59.7 M | - | 39.6 M | 36.9 M | 32 M | - | 31.4 M | 30.7 M | 26.8 M | - | 22.2 M | 21.1 M | 19.7 M | - | 20 M | 13.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 60.5 M | 54.4 M | 50.6 M | 44.1 M | 39.4 M | 38 M | 40 M | 33.8 M | 28.4 M | 27.3 M | 26.6 M | 25.2 M | 22.5 M | 16.6 M | 18.5 M | 16.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
16.8 M | 13.9 M | 6.58 M | - | -7.83 M | 5.47 M | 3.75 M | - | 4.69 M | 19.4 M | 31.3 M | - | 52.7 M | 63.2 M | 60 M | - | 45.2 M | 48.2 M | 36.4 M | - | 21 M | 19.5 M | 11.9 M | - | 7.96 M | 11.1 M | 11.2 M | - | 7.89 M | 4.27 M | 5.98 M | 3.26 M | -406 K | 5.47 M | 5.68 M | 2.9 M | 3.75 M | 5.86 M | 3.46 M | 1.43 M | 3.69 M | 4.61 M | 4.04 M | 61 K | 2.22 M | 3.11 M | 5.31 M | 5.18 M | 8.04 M | 6.1 M | 3.54 M | 6.41 M | 2.19 M | 1.32 M | 1.17 M | -1.54 M | 552 K | -121 K | -2.09 M |
Interest Expense |
-804 K | 3.5 M | -286 K | - | 3.1 M | -215 K | -3.54 M | - | 895 K | 274 K | 270 K | - | 329 K | 271 K | 292 K | - | 2.86 M | 3.14 M | 2.75 M | - | 3.05 M | 3 M | 2.98 M | - | 2.86 M | 1.74 M | 1.73 M | - | 1.69 M | 1.67 M | 1.65 M | 1.64 M | 1.62 M | 1.6 M | 1.58 M | 1.57 M | 1.56 M | 638 K | 5 K | 8 K | 8 K | 8 K | 9 K | 12 K | 11 K | 13 K | 14 K | -54 K | 11.7 K | 12.4 K | 13.5 K | 14 K | -7 K | 27.4 K | 22.4 K | 28 K | 13.5 K | 13.5 K | 13 K |
EBITDA |
26.7 M | 24.2 M | 25.3 M | - | 768 K | 14.2 M | 20.7 M | - | 12.3 M | 26.9 M | 46.5 M | - | 59.3 M | 69.8 M | 71.8 M | - | 72.6 M | 52 M | 44.8 M | - | 40.5 M | 32.4 M | 18.3 M | - | 22.8 M | 20.1 M | 15.4 M | - | 19.7 M | 12.2 M | 9.94 M | 3.26 M | 5.97 M | 8.75 M | 7.26 M | 2.9 M | 7.59 M | 8.32 M | 4.61 M | 1.43 M | 7.14 M | 6.9 M | 5.19 M | 61 K | 5.18 M | 4.96 M | 6.2 M | 5.18 M | 10.3 M | 7.61 M | 4.36 M | 6.41 M | 4.78 M | 3.01 M | 1.99 M | -1.54 M | 1.76 M | 285 K | -1.69 M |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 91.2 M | 73.1 M | 67.9 M | 64.2 M | 63.6 M | 61.5 M | 59.6 M | 49.5 M | 44.1 M | 41.6 M | 43.5 M | 38.9 M | 38.3 M | 37 M | 27 M | 24.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
73.7 M | 71.2 M | 71.3 M | - | 75.6 M | 65.5 M | 61.8 M | - | 55.6 M | 49 M | 56.2 M | - | 53.6 M | 54.6 M | 54.3 M | - | 48.4 M | 44.3 M | 39.1 M | - | 29.1 M | 26.7 M | 27.5 M | - | 24.6 M | 23.7 M | 19 M | - | 15.9 M | 16.6 M | 15.9 M | 16.1 M | 15 M | 11.2 M | 9.18 M | 8.57 M | 7.13 M | 8.14 M | 7.02 M | 6.47 M | 5.96 M | 6.24 M | 6.02 M | 4.98 M | 4.47 M | 4.33 M | 3.38 M | 3.37 M | 2.9 M | 3.12 M | 3.31 M | 3.25 M | 3.13 M | 3.42 M | 3.43 M | 4.27 M | 2.49 M | 2.29 M | 2.44 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Repligen Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
$ 154.51 | -1.17 % | $ 44.4 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 9.4 | -11.74 % | $ 22.8 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 56.83 | 1.05 % | $ 2.86 B | USA |
 |
ICU Medical
ICUI
|
$ 123.31 | -1.53 % | $ 3.04 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 452.07 | -2.67 % | $ 161 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 5.2 | 2.16 % | $ 231 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
AngioDynamics
ANGO
|
$ 10.31 | -13.65 % | $ 421 M | USA |
 |
Repro Med Systems
KRMD
|
$ 4.32 | 1.17 % | $ 200 M | USA |
 |
AtriCure
ATRC
|
$ 29.07 | 2.68 % | $ 1.39 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 23.0 | -0.13 % | $ 1.55 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.29 | -0.11 % | $ 192 M | USA |
 |
Masimo Corporation
MASI
|
$ 178.59 | 0.33 % | $ 9.52 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 116.8 | -1.2 % | $ 3.74 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 67.7 | -0.78 % | $ 4 B | USA |
 |
BioLife Solutions
BLFS
|
$ 19.51 | 1.14 % | $ 899 M | USA |
 |
electroCore
ECOR
|
$ 6.8 | 3.03 % | $ 57.7 K | USA |
 |
STERIS plc
STE
|
$ 218.71 | -0.56 % | $ 21.6 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 117.81 | -0.52 % | $ 5.26 B | USA |
 |
Utah Medical Products
UTMD
|
$ 63.12 | 0.4 % | $ 205 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.08 | 0.98 % | $ 226 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 254.8 | 0.82 % | $ 18.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.63 | -0.26 % | $ 2.32 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 112.77 | 0.12 % | $ 5.46 B | USA |
 |
ResMed
RMD
|
$ 224.09 | 0.56 % | $ 32.7 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Baxter International
BAX
|
$ 16.68 | -0.6 % | $ 8.56 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 20.21 | 4.55 % | $ 1 B | USA |
 |
Stereotaxis
STXS
|
$ 1.87 | 1.08 % | $ 170 M | USA |
 |
The Cooper Companies
COO
|
$ 70.17 | -1.76 % | $ 14 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 108.49 | -0.24 % | $ 2.46 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.4 | 1.27 % | $ 110 M |  Israel |
 |
Nephros
NEPH
|
$ 2.87 | -2.21 % | $ 29.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 25.81 | -0.35 % | $ 4.34 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.28 | -4.86 % | $ 23 M | USA |
 |
Alcon
ALC
|
$ 74.56 | -1.26 % | $ 40.4 B |  Schweiz |
 |
Pro-Dex
PDEX
|
$ 51.67 | 1.33 % | $ 170 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.69 | 2.99 % | $ 20.7 M | USA |